VOR Protein Complex Inhibition for Blocking Viral Nuclear Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and viral diseases, such as HIV, face challenges including drug resistance, inadequate targeting of affected cells, and inefficiencies in disrupting intercellular communication and viral infection pathways, leading to advanced disease stages.
Innovation Solution
Inhibition of the tripartite VAP-A, ORP3, and Rab7 protein complex, which mediates intercellular communication and viral infection by disrupting the transport of endocytosed biomaterials to the nucleus, using agents like Itraconazole or its analogues, to prevent drug resistance and target disease pathways effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy or antiviral therapy is used, then initial treatment effectiveness is achieved, but drug resistance develops leading to treatment failure
Solution Approach 1:
The patent extracts and targets the specific VOR protein complex (VAP-A, ORP3, Rab7) that mediates viral entry and intercellular communication, separating this critical pathway from general cellular functions. By focusing on this specific complex rather than broad cellular processes, the treatment achieves high specificity and avoids the non-specific toxicity and resistance issues of conventional chemotherapy and antiviral therapies.
Solution Approach 2:
The patent uses small molecule inhibitors as intermediaries to block the VOR protein complex interaction. These inhibitors act as mediators that prevent the formation of the VOR complex without directly attacking viral particles or cancer cells, thereby disrupting the pathological communication and entry pathways while maintaining cellular viability and avoiding drug resistance.
2Productivity
If antiangiogenic agents or cytotoxic drugs are used, then tumor growth is initially suppressed, but tumors become more aggressive and develop resistance
Solution Approach 1:
The patent applies preliminary action by blocking the VOR protein complex pathway before tumors can develop resistance mechanisms. The inhibitor prevents the formation of the protein complex that mediates viral entry and intercellular communication, thereby preemptively stopping the pathways that tumors exploit for survival and adaptation, before resistant phenotypes can emerge.
Solution Approach 2:
Instead of attacking tumor cells directly with cytotoxic drugs that select for resistant clones, the patent inverts the approach by targeting the protective communication pathways that tumors use. By blocking the VOR complex-mediated pathways that tumors exploit for survival and intercellular communication, the treatment undermines tumor adaptability rather than selecting for resistant variants.
3Reliability
If traditional immunotherapeutic strategies are employed, then immune response is enhanced, but challenges in cell targeting and stability reduce effectiveness
Solution Approach 1:
The patent replaces complex mechanical cell targeting systems with small molecule inhibitors that can systemically distribute and selectively bind to the VOR protein complex. Instead of using engineered cells or complex delivery systems that require precise targeting mechanisms, the small molecule inhibitor passively distributes throughout the body and selectively binds to the pathological VOR complex in infected or cancerous cells, greatly simplifying the therapeutic approach.
Data Source
AI summary
The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and/or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.